1. The vaccinia‐based Sementis Copenhagen Vector coronavirus disease 2019 vaccine induces broad and durable cellular and humoral immune responses.
- Author
-
Eldi, Preethi, Cooper, Tamara H, Prow, Natalie A, Liu, Liang, Heinemann, Gary K, Zhang, Voueleng J, Trinidad, Abigail D, Guzman‐Genuino, Ruth Marian, Wulff, Peter, Hobbs, Leanne M, Diener, Kerrilyn R, and Hayball, John D
- Subjects
COVID-19 ,SARS-CoV-2 ,DISEASE vectors ,CYTOTOXIC T cells - Abstract
The ongoing coronavirus disease 2019 (COVID‐19) pandemic perpetuated by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants has highlighted the continued need for broadly protective vaccines that elicit robust and durable protection. Here, the vaccinia virus‐based, replication‐defective Sementis Copenhagen Vector (SCV) was used to develop a first‐generation COVID‐19 vaccine encoding the spike glycoprotein (SCV‐S). Vaccination of mice rapidly induced polyfunctional CD8 T cells with cytotoxic activity and robust type 1 T helper‐biased, spike‐specific antibodies, which are significantly increased following a second vaccination, and contained neutralizing activity against the alpha and beta variants of concern. Longitudinal studies indicated that neutralizing antibody activity was maintained up to 9 months after vaccination in both young and middle‐aged mice, with durable immune memory evident even in the presence of pre‐existing vector immunity. Therefore, SCV‐S vaccination has a positive immunogenicity profile, with potential to expand protection generated by current vaccines in a heterologous boost format and presents a solid basis for second‐generation SCV‐based COVID‐19 vaccine candidates incorporating additional SARS‐CoV‐2 immunogens. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF